News

Prokarium Achieves Major Milestone with FDA’s IND Approval for Bladder Cancer Program

London, UK – November 2, 2023 – Prokarium, a biopharmaceutical company at the forefront of applying synthetic biology to create...

Prokarium Achieves Major Milestone with FDA’s IND Approval for Bladder Cancer Program

London, UK – November 2, 2023 – Prokarium, a biopharmaceutical company at the forefront of applying synthetic biology to create...

Prokarium Announces $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic Platform

London, UK February 9, 2023 – Prokarium, a biopharmaceutical company leading the oncology field of microbial immunotherapy, has...

Prokarium Announces $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic Platform

London, UK February 9, 2023 – Prokarium, a biopharmaceutical company leading the oncology field of microbial immunotherapy, has...

Prokarium and Ginkgo Bioworks Announce Partnership to Discover Multiple Targets for RNA Therapeutics and Immuno-oncology

LONDON, UK and BOSTON, MA — January 9, 2023 — Prokarium, a biopharmaceuticalcompany pioneering the oncology field of...

Prokarium and Ginkgo Bioworks Announce Partnership to Discover Multiple Targets for RNA Therapeutics and Immuno-oncology

LONDON, UK and BOSTON, MA — January 9, 2023 — Prokarium, a biopharmaceuticalcompany pioneering the oncology field of...

Prokarium Strengthens Manufacturing Capabilities with Appointment of Peter Juul Madsen as Vice President of CMC

LONDON, UK – October 19, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...

Prokarium Strengthens Manufacturing Capabilities with Appointment of Peter Juul Madsen as Vice President of CMC

LONDON, UK – October 19, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...

Prokarium Strengthens Patent Position Through Notice of Allowance of US Patent for Immunotherapy Prime in Combination with Cell Therapies

LONDON, United Kingdom, October 5, 2022 – Prokarium Ltd (‘Prokarium’ or the ‘Company’), a biopharmaceutical company pioneering the...

Prokarium Strengthens Patent Position Through Notice of Allowance of US Patent for Immunotherapy Prime in Combination with Cell Therapies

LONDON, United Kingdom, October 5, 2022 – Prokarium Ltd (‘Prokarium’ or the ‘Company’), a biopharmaceutical company pioneering the...

Prokarium Exercises Option for an Exclusive Worldwide License for the Use of Salmonella Immunotherapy in the Treatment of Bladder Cancer

LONDON, UK – March 2, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...

Prokarium Exercises Option for an Exclusive Worldwide License for the Use of Salmonella Immunotherapy in the Treatment of Bladder Cancer

LONDON, UK – March 2, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...

Prokarium Expands R&D Capabilities with London Biofoundry to Deepen Microbial Immunotherapy Pipeline

LONDON, UK – January 26, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...

Prokarium Expands R&D Capabilities with London Biofoundry to Deepen Microbial Immunotherapy Pipeline

LONDON, UK – January 26, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...

Prokarium Shares Preclinical Proof-of-Concept Data on Its Microbial Immunotherapy Bladder Cancer Program at SITC 2021

LONDON, UK – November 11, 2021– Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, today...

Prokarium Shares Preclinical Proof-of-Concept Data on Its Microbial Immunotherapy Bladder Cancer Program at SITC 2021

LONDON, UK – November 11, 2021– Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, today...